Johnson & Johnson JNJ · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500Dow Jones
276.22
+1.43%
Close of 6 Nov 2026, in USD
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $665.66bn
- Last close × shares
- Volume
- 8.9m
- Shares, 6 Nov 2026
- Price to earnings
- 25.0
- Dividend yield
- 1.91%
About Johnson & Johnson
From its filings with the US Securities and Exchange Commission
Johnson & Johnson is based in New Brunswick, New Jersey and is incorporated in New Jersey. Its shares trade on NYSE under the ticker JNJ. It is a member of the S&P 500 and Dow Jones. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 28 December 2025, it reported revenue of $94.19bn and net income of $26.80bn. At that date it held total assets of $199.21bn and shareholders' equity of $81.54bn. By region, United States accounted for 57.1%, followed by Non-US at 42.9%.
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a wide range of acute and elective procedures. These products are designed to address disease states where procedural intervention plays a central role in treatment and patient outcomes.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 28 Dec 2025
- DARZALEX $14.35bn · 15.2%
- Stelara $6.08bn · 6.5%
- ELECTROPHYSIOLOGY $5.63bn · 6.0%
- GENERAL $5.56bn · 5.9%
Latest on Johnson & Johnson
Our reporting
Next results
Due on 20 Jan 2027. Analysts expect earnings of 2.91 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Johnson & Johnson's ticker?
Johnson & Johnson trades as JNJ on its US listing, under ISIN US4781601046.
What was Johnson & Johnson's last closing price?
276.22 on 6 Nov 2026. The figure is in USD and is never converted.
When does Johnson & Johnson next report results?
Results are expected on 20 Jan 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.